ABSTRACT
Despite vaccination programs, pertussis has been poorly controlled, especially among older adults in Australia. This longitudinal, retrospective, observational study aimed to estimate the incidence and risk factors of pertussis among persons ≥50 years of age in Australia in the primary care setting, including those with underlying chronic obstructive pulmonary disease (COPD) or asthma. We used the IQVIA general practitioner electronic medical record database to identify patients ≥50 years of age with a clinical diagnosis of pertussis during 2015-2019. Pertussis incidence rates ranged from 57.6 to 91.4 per 100,000 persons and were higher among women and highest in those 50-64 years of age. Patients with COPD or asthma had higher incidence rates and an increased risk for pertussis compared with the overall population ≥50 years of age. Our findings suggest that persons ≥50 years of age in Australia with COPD or asthma have a higher incidence of and risk for pertussis diagnosis.
Subject(s)
Asthma , Pulmonary Disease, Chronic Obstructive , Whooping Cough , Aged , Female , Humans , Asthma/epidemiology , Australia/epidemiology , Incidence , Retrospective Studies , Risk Factors , Whooping Cough/epidemiologyABSTRACT
Introduction: Influenza and pneumococcal vaccines are the most regularly prescribed vaccines amongst adults <65 years of age. Pertussis booster vaccines (available as combined diphtheria-tetanus-acellular pertussis, Tdap) uptake is relatively low in many countries in the Asia-Pacific region. Increasing Tdap vaccination is a strategy that may aid healthy aging.Areas Covered: Epidemiology data, including notification reports from 6 advanced economies in Asia (Australia, Hong Kong, New Zealand, Singapore, South Korea, and Taiwan) were reviewed to assess the pertussis disease burden and identify high-risk groups. Existing Tdap vaccination recommendations were reviewed. Current vaccination practices were discussed to benchmark and identify barriers and success factors for Tdap booster vaccination in older adults.Expert Opinion: The available evidence supports Tdap vaccination at an individual level for the prevention of pertussis, along with tetanus and diphtheria in those aged 65+ years, together with influenza and pneumococcal vaccination. Data gaps need to be filled to support the development of national/supranational recommendations for pertussis booster vaccination. Groups at higher risk of pertussis infection and its complications, including those with chronic obstructive pulmonary disease and asthma, could be considered as priority groups. Increasing disease awareness and establishing adult vaccination registries could improve vaccine coverage and promote healthy aging.
PLAIN LANGUAGE SUMMARYPertussis, also called whooping cough, is a common disease in adults. However, how it affects adults in some countries in the Asia-Pacific region is not well understood. In 2019, a panel of experts met to review the available information on adult cases of pertussis in Australia, Hong Kong, New Zealand, Singapore, South Korea, and Taiwan. Here, we present the outcomes of the meeting. Pertussis is increasingly reported in the Asia-Pacific region, including cases diagnosed in adults. The diagnosis may be missed in countries where awareness is still low and/or it is not tested routinely. The experts concluded that physicians should consider recommending pertussis vaccination to older adults (aged 65 or older) on an individual basis, as well as people with asthma or chronic obstructive pulmonary disease, who appear to be at higher risk of severe pertussis. Uptake of pertussis vaccination in adults could be improved by increasing awareness of the vaccines available and vaccination infrastructure for this age-group. Some of the measures proposed were as follows: improved access to vaccination; personalized reminders when vaccines are due; and more education about pertussis in adults for doctors, nursesnurses, and patients. The experts also proposed setting up adult vaccination registries for tracking and evaluation of vaccine uptake. This expert opinion might help the healthcare community build action plans to recognise the burden of the disease and increase rates of vaccination among adults. In addition, better data on the disease burden would help to generate awareness.
Subject(s)
Diphtheria-Tetanus-acellular Pertussis Vaccines , Diphtheria , Tetanus , Whooping Cough , Aged , Antibodies, Bacterial , Diphtheria/prevention & control , Humans , Tetanus/prevention & control , Vaccination , Whooping Cough/epidemiology , Whooping Cough/prevention & controlABSTRACT
BACKGROUND: General practitioners play an important role in the detection and clinical management of influenza. The Australian Sentinel Practice Research Network (ASPREN) has been collecting data from sentinel GPs on selected conditions, including influenza-like illness (ILI), since 1991 to inform public health authorities of communicable disease activity in the community. METHODS: Weekly incidence of ILI data reported by ASPREN GPs in 2007-2008 was compared with data from two separate surveillance systems: New South Wales data from FluTracking, an online self reporting ILI surveillance system; and national laboratory notifications of influenza reported to the National Notifiable Diseases Surveillance System between 2003 and 2008. RESULTS: ASPREN recorded peak ILI rates of 47 per 1000 consultations in week 30 (ending 29 July) 2007 and 34 per 1000 consultations in week 36 (ending 7 September) 2008. Similar trends in incidence were seen in FluTracking cough and fever rates, ASPREN data in New South Wales and National Notifiable Diseases Surveillance System laboratory notifications. DISCUSSION: Data captured by the three separate surveillance systems provide complementary information regarding influenza in the Australian population.
Subject(s)
Disease Notification/methods , Disease Outbreaks/statistics & numerical data , Infection Control/methods , Influenza, Human/epidemiology , Population Surveillance/methods , Public Health , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Influenza, Human/prevention & control , Male , Middle Aged , New South Wales/epidemiology , Retrospective Studies , Young AdultABSTRACT
From 1 July 2007 two new rotavirus vaccines licensed for use in Australia (RotaTeq CSL Biotherapies/Merck and Rotarix Glaxo Smith Kline) will be funded for the National Immunisation Program. The vaccines differ with respect to their composition and the timing and mode of administration. Both have been evaluated in huge randomised trials and shown to be highly effective in preventing rotavirus gastroenteritis, including severe disease requiring hospital admission. Neither has been associated with an increased rate of intussusception; however, surveillance for adverse effects following vaccination will be important. As rotavirus infection is ubiquitous in young children, funding of this vaccine will significantly decrease the enormous morbidity and costs associated with this disease in our community.
Subject(s)
Gastroenteritis/prevention & control , Rotavirus Infections/prevention & control , Rotavirus Vaccines/administration & dosage , Australia , Child, Preschool , Humans , Immunization Programs , Infant , Randomized Controlled Trials as Topic , RotavirusABSTRACT
SA HealthPlus, one of nine national Australian coordinated care trials, addressed chronic illness care by testing whether coordinated care would improve health outcomes at the cost of usual care. SA HealthPlus compared a generic model of coordinated care for 3,115 intervention patients with the usual care for 1,488 controls. Service coordinators and the behavioral and care-planning approach were new. The health status (SF-36) in six of eight projects improved, and those patients who had been hospitalized in the year immediately preceding the trial were the most likely to save on costs. A mid-trial review found that health benefits from coordinated care depended more on patients' self-management than the severity of their illness, a factor leading to the Flinders Model of Self-Management Support.